Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

TYRA 10.23.2024

Full Press ReleaseSEC FilingsOur TYRA Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
  • 01.10.2025 - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
  • 01.07.2025 - Eliana Merle

Recent Filings

  • 01.22.2025 - 144 Report of proposed sale of securities
  • 01.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities

CARLSBAD, Calif.,Oct. 23, 2024/PRNewswire/ --Tyra Biosciences, Inc.(Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast onOctober 25, 2024at8:00 am ETto share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36thEORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being heldOctober 23-25, 2024, inBarcelona, Spain.

Gary Steinberg, MD,Professor of Urology,Department of Urology,Rush University Medical Center, will be joining members of TYRA's management team on the call and will be available during Q&A.

Conference Call Information

TYRA is hosting a conference call and webcast onOctober 25, 2024, at8am ETto review the interim clinical data demonstrated with TYRA-300 in mUC. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website athttps://ir.tyra.bio. To participate via telephone, please register in advance at thislink. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.

AboutTyra Biosciences

Tyra Biosciences, Inc.(Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based inCarlsbad, CA.

For more information about our science, pipeline and people, please visitwww.tyra.bioand engage with us onLinkedIn.

Contact:

Amy Conradaconrad@tyra.bio

(PRNewsfoto/Tyra Biosciences, Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-host-conference-call-on-interim-clinical-data-of-tyra-300-from-surf301-phase-12-study-on-october-25-2024-at-8am-et-302285111.html

SOURCETyra Biosciences

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com